Cullinan Therapeutics Inc (NASDAQ:CGEM), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication.
In SLE, the immune system of the body mistakenly attacks healthy tissue.
The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated safety profile?.
The company plans to submit an investigational new drug application to study CLN-978 in patients with SLE in the third quarter of 2024 and is also planning for future development in other autoimmune diseases.
Cullinan Therapeutics has discontinued enrollment in its B cell non-Hodgkin lymphoma (B-NHL) study to focus ongoing development on autoimmune indications.
Recent data demonstrated the potential of CD19-directed CAR T therapies in 15 patients with autoimmune ...